These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31847742)

  • 21. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
    Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report.
    Casanova C; Verlicchi A; Mazza V; Dazzi C
    Future Oncol; 2015; 11(15 Suppl):9-15. PubMed ID: 26235259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
    Schwartzberg L; McIntyre K; Wilks S; Puhalla S; O'Shaughnessy J; Berrak E; He Y; Vahdat L
    BMC Cancer; 2019 Jun; 19(1):578. PubMed ID: 31195996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.
    Gumusay O; Huppert LA; Magbanua MJM; Wabl CA; Assefa M; Chien AJ; Melisko ME; Majure MC; Moasser M; Park J; Rugo HS
    Breast Cancer Res Treat; 2024 Jan; 203(2):197-204. PubMed ID: 37815684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).
    Bischoff J; Barinoff J; Mundhenke C; Bauerschlag DO; Costa SD; Herr D; Lübbe K; Marmé F; Maass N; von Minckwitz G; Grischke EM; Müller V; Schmidt M; Gerber B; Kümmel S; Schumacher C; Krabisch P; Seiler S; Thill M; Nekljudova V; Loibl S
    Anticancer Drugs; 2019 Apr; 30(4):394-401. PubMed ID: 30875348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
    Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
    Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
    Maeda S; Saimura M; Minami S; Kurashita K; Nishimura R; Kai Y; Yano H; Mashino K; Mitsuyama S; Shimokawa M; Tamura K;
    Breast; 2017 Apr; 32():66-72. PubMed ID: 28056400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
    Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
    Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.
    Inoue K; Ninomiya J; Saito T; Okubo K; Nakakuma T; Yamada H; Kimizuka K; Higuchi T;
    Invest New Drugs; 2019 Jun; 37(3):538-547. PubMed ID: 30848403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.
    Balch SM; Vaz-Luis I; Li T; Tayob N; Jain E; Helvie K; Buendia-Buendia JE; Shannon E; Isakoff SJ; Tung NM; Krop IE; Lin NU; Wagle N; Freedman RA
    Breast Cancer Res Treat; 2021 Sep; 189(2):411-423. PubMed ID: 34302589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
    Aogi K; Watanabe K; Kitada M; Sangai T; Ohtani S; Aruga T; Kawaguchi H; Fujisawa T; Maeda S; Morimoto T; Sato N; Takao S; Morita S; Masuda N; Toi M; Ohno S
    Int J Clin Oncol; 2021 Jul; 26(7):1229-1236. PubMed ID: 33891194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
    Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
    Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.
    Hurvitz SA; Dalenc F; Campone M; O'Regan RM; Tjan-Heijnen VC; Gligorov J; Llombart A; Jhangiani H; Mirshahidi HR; Tan-Chiu E; Miao S; El-Hashimy M; Lincy J; Taran T; Soria JC; Sahmoud T; André F
    Breast Cancer Res Treat; 2013 Oct; 141(3):437-46. PubMed ID: 24101324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Sotelo MJ; García-Sáenz JA; Manso L; Moreno F; Ciruelos E; Callata HR; Mendiola C; Cabezas S; Ghanem I; Díaz-Rubio E
    J Cancer Res Ther; 2014; 10(4):967-72. PubMed ID: 25579538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
    Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
    Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
    Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
    Blackwell KL; Zaman K; Qin S; Tkaczuk KHR; Campone M; Hunt D; Bryce R; Goldstein LJ;
    Clin Breast Cancer; 2019 Apr; 19(2):97-104.e4. PubMed ID: 30655172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.
    Pedersini R; Vassalli L; Claps M; Tulla A; Rodella F; Grisanti S; Amoroso V; Roca E; Simoncini EL; Berruti A
    Oncology; 2018; 94 Suppl 1(Suppl 1):10-15. PubMed ID: 30036867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.